EP1355666B1
(en)
|
2000-12-22 |
2012-06-13 |
Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. |
Use of repulsive guidance molecule (RGM) and its modulators
|
TW200714610A
(en)
|
2005-02-16 |
2007-04-16 |
Univ Maryland |
CXCR3 is a gliadin receptor
|
JP2012228248A
(ja)
*
|
2005-08-19 |
2012-11-22 |
Abbott Lab |
二重可変ドメイン免疫グロブリン及びその使用
|
US7612181B2
(en)
*
|
2005-08-19 |
2009-11-03 |
Abbott Laboratories |
Dual variable domain immunoglobulin and uses thereof
|
CA2624562A1
(en)
|
2005-09-30 |
2007-04-12 |
Abbott Gmbh & Co. Kg |
Binding domains of proteins of the repulsive guidance molecule (rgm) protein family and functional fragments thereof, and their use
|
RU2473362C2
(ru)
|
2007-02-01 |
2013-01-27 |
Акселерон Фарма Инк. |
АНТАГОНИСТЫ АКТИВИНА-ActRIIa-Fc И ИХ ПРИМЕНЕНИЕ ДЛЯ ЛЕЧЕНИЯ ИЛИ ПРОФИЛАКТИКИ РАКА МОЛОЧНОЙ ЖЕЛЕЗЫ
|
EA025371B1
(ru)
|
2007-02-09 |
2016-12-30 |
Акселерон Фарма Инк. |
АНТАГОНИСТЫ АКТИВИНА-ActRIIa И ПРИМЕНЕНИЕ ДЛЯ СТИМУЛЯЦИИ РОСТА КОСТИ У БОЛЬНЫХ РАКОМ
|
AU2008233196B2
(en)
|
2007-03-30 |
2011-10-13 |
Abbvie Inc. |
Recombinant expression vector elements (rEVEs) for enhancing expression of recombinant proteins in host cells
|
WO2008134659A2
(en)
|
2007-04-27 |
2008-11-06 |
Zymogenetics, Inc. |
Antagonists to il-17a, il-17f, and il-23p19 and methods of use
|
US9322035B2
(en)
|
2007-05-31 |
2016-04-26 |
Genmab A/S |
Recombinant IgG4 monovalent antibodies
|
BRPI0813452A2
(pt)
|
2007-06-14 |
2017-05-23 |
Galactica Pharmaceuticals Inc |
protéinas de fusão rage.
|
KR101432191B1
(ko)
*
|
2007-06-22 |
2014-08-20 |
훗카이도 코리츠 다이가쿠 호진 삿포르 이카 다이가쿠 |
이식편대숙주 질환의 검출 또는 치료 방법
|
AU2008282218A1
(en)
|
2007-07-31 |
2009-02-05 |
Medimmune, Llc |
Multispecific epitope binding proteins and uses thereof
|
ES2628395T3
(es)
*
|
2007-08-15 |
2017-08-02 |
Bayer Pharma Aktiengesellschaft |
Anticuerpo regulado por proteasa
|
EP3243524A1
(en)
|
2007-09-18 |
2017-11-15 |
Acceleron Pharma Inc. |
Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
|
CN101842387B
(zh)
|
2007-09-26 |
2014-05-07 |
Ucb医药有限公司 |
双特异性抗体融合物
|
BRPI0819656A2
(pt)
|
2007-11-27 |
2015-06-23 |
Ablynx Nv |
Seqüências de aminoácidos contras citocinas heterodiméricas e/ou seus receptores e polipeptídeos compreendendo as mesmas
|
EP2615115A3
(en)
*
|
2007-11-30 |
2014-01-08 |
Glaxo Group Limited |
Antigen-binding constructs
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
US20110189206A1
(en)
|
2008-01-03 |
2011-08-04 |
Barbas Iii Carlos F |
Antibody Targeting Through a Modular Recognition Domain
|
US8557242B2
(en)
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
ERBB2 antibodies comprising modular recognition domains
|
US8557243B2
(en)
|
2008-01-03 |
2013-10-15 |
The Scripps Research Institute |
EFGR antibodies comprising modular recognition domains
|
US8454960B2
(en)
|
2008-01-03 |
2013-06-04 |
The Scripps Research Institute |
Multispecific antibody targeting and multivalency through modular recognition domains
|
US8574577B2
(en)
|
2008-01-03 |
2013-11-05 |
The Scripps Research Institute |
VEGF antibodies comprising modular recognition domains
|
CN102065892A
(zh)
*
|
2008-01-30 |
2011-05-18 |
雅培制药有限公司 |
用于使抗体片段结晶的组合物和方法
|
US8962803B2
(en)
|
2008-02-29 |
2015-02-24 |
AbbVie Deutschland GmbH & Co. KG |
Antibodies against the RGM A protein and uses thereof
|
EP2281845B1
(en)
*
|
2008-04-25 |
2020-09-02 |
Kyowa Kirin Co., Ltd. |
Stable polyvalent antibody
|
US20100260668A1
(en)
*
|
2008-04-29 |
2010-10-14 |
Abbott Laboratories |
Dual Variable Domain Immunoglobulins and Uses Thereof
|
SG190572A1
(en)
*
|
2008-04-29 |
2013-06-28 |
Abbott Lab |
Dual variable domain immunoglobulins and uses thereof
|
KR20110016959A
(ko)
*
|
2008-06-03 |
2011-02-18 |
아보트 러보러터리즈 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
AR072001A1
(es)
*
|
2008-06-03 |
2010-07-28 |
Abbott Lab |
Inmunoglobulina con dominio variable dual y usos de la misma
|
KR20110044991A
(ko)
*
|
2008-07-02 |
2011-05-03 |
이머전트 프로덕트 디벨롭먼트 시애틀, 엘엘씨 |
TNF-α 길항제 다-표적 결합 단백질
|
RU2011104348A
(ru)
*
|
2008-07-08 |
2012-08-20 |
Эбботт Лэборетриз (Us) |
Иммуноглобулины с двойным вариабельным доменом против простагландина е2 и их применение
|
US8216997B2
(en)
|
2008-08-14 |
2012-07-10 |
Acceleron Pharma, Inc. |
Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
|
WO2010028796A1
(en)
*
|
2008-09-10 |
2010-03-18 |
F. Hoffmann-La Roche Ag |
Trispecific hexavalent antibodies
|
WO2010035012A1
(en)
|
2008-09-26 |
2010-04-01 |
Ucb Pharma S.A. |
Biological products
|
KR102362774B1
(ko)
|
2008-09-30 |
2022-02-15 |
아블렉시스, 엘엘씨 |
키메라 항체의 제조를 위한 인간 이외의 포유동물
|
US8268314B2
(en)
|
2008-10-08 |
2012-09-18 |
Hoffmann-La Roche Inc. |
Bispecific anti-VEGF/anti-ANG-2 antibodies
|
NZ614351A
(en)
|
2008-11-10 |
2015-05-29 |
Alexion Pharma Inc |
Methods and compositions for treating complement-associated disorders
|
AU2009334498A1
(en)
|
2008-12-31 |
2011-07-21 |
Biogen Idec Ma Inc. |
Anti-lymphotoxin antibodies
|
AU2010208637A1
(en)
*
|
2009-01-29 |
2011-08-04 |
Abbvie Inc. |
IL-1 binding proteins
|
EP2401298A1
(en)
*
|
2009-02-24 |
2012-01-04 |
Glaxo Group Limited |
Antigen-binding constructs
|
PE20160651A1
(es)
|
2009-03-05 |
2016-07-24 |
Abbvie Inc |
Proteinas de union a il-17
|
EP3444359A1
(en)
*
|
2009-03-12 |
2019-02-20 |
Cancer Prevention And Cure, Ltd. |
Methods of identification of non-small cell lung cancer
|
AU2010232693B2
(en)
|
2009-03-30 |
2016-04-21 |
Acceleron Pharma Inc. |
BMP-ALK3 antagonists and uses for promoting bone growth
|
WO2010112193A1
(en)
|
2009-04-02 |
2010-10-07 |
Roche Glycart Ag |
Multispecific antibodies comprising full length antibodies and single chain fab fragments
|
WO2010112194A1
(en)
|
2009-04-02 |
2010-10-07 |
F. Hoffmann-La Roche Ag |
Antigen-binding polypeptides and multispecific antibodies comprising them
|
KR20110124369A
(ko)
|
2009-04-07 |
2011-11-16 |
로슈 글리카트 아게 |
이중특이적 항erbb3/항cmet 항체
|
KR20110124368A
(ko)
|
2009-04-07 |
2011-11-16 |
로슈 글리카트 아게 |
이중특이적 항―erbb―2/항―c―met 항체
|
PT2417156E
(pt)
|
2009-04-07 |
2015-04-29 |
Roche Glycart Ag |
Anticorpos trivalentes, biespecíficos
|
BRPI1012193A2
(pt)
*
|
2009-05-01 |
2019-09-24 |
Abbott Lab |
imunoglobulinas de domínio variável duplo e usos das mesmas
|
MX2011011670A
(es)
*
|
2009-05-01 |
2011-11-18 |
Abbott Lab |
Inmunoglobulinas de dominio variable dual y usos de las mismas.
|
WO2010129406A2
(en)
*
|
2009-05-04 |
2010-11-11 |
The Johns Hopkins University |
Methods of promoting muscle growth
|
AU2010252284A1
(en)
|
2009-05-27 |
2011-11-17 |
F. Hoffmann-La Roche Ag |
Tri- or tetraspecific antibodies
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
WO2010151526A1
(en)
|
2009-06-23 |
2010-12-29 |
Alexion Pharmaceuticals, Inc. |
Bispecific antibodies that bind to complement proteins
|
UY32808A
(es)
*
|
2009-07-29 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas como dominio variable dual y usos de las mismas
|
US9345661B2
(en)
|
2009-07-31 |
2016-05-24 |
Genentech, Inc. |
Subcutaneous anti-HER2 antibody formulations and uses thereof
|
GB2472856B
(en)
|
2009-08-21 |
2012-07-11 |
Cantargia Ab |
IL1-RAP modulators and uses thereof
|
NZ598524A
(en)
|
2009-08-29 |
2014-06-27 |
Abbvie Inc |
Therapeutic dll4 binding proteins
|
IN2012DN02737A
(no)
*
|
2009-09-01 |
2015-09-11 |
Abbott Lab |
|
ES2667258T3
(es)
|
2009-09-10 |
2018-05-10 |
Ucb Biopharma Sprl |
Anticuerpos multivalentes
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
SG179196A1
(en)
|
2009-09-16 |
2012-04-27 |
Genentech Inc |
Coiled coil and/or tether containing protein complexes and uses thereof
|
GB201005063D0
(en)
|
2010-03-25 |
2010-05-12 |
Ucb Pharma Sa |
Biological products
|
WO2011047262A2
(en)
*
|
2009-10-15 |
2011-04-21 |
Abbott Laboratories |
Dual variable domain immunoglobulins and uses thereof
|
UY32979A
(es)
*
|
2009-10-28 |
2011-02-28 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
CN102741289B
(zh)
*
|
2009-11-11 |
2016-08-03 |
加尼梅德药物公司 |
密蛋白6(cldn6)特异性的抗体
|
WO2011071871A1
(en)
*
|
2009-12-07 |
2011-06-16 |
The Board Of Trustees Of The Leland Stanford Junior University |
Methods for enhancing anti-tumor antibody therapy
|
US9175075B2
(en)
|
2009-12-08 |
2015-11-03 |
AbbVie Deutschland GmbH & Co. KG |
Methods of treating retinal nerve fiber layer degeneration with monoclonal antibodies against a retinal guidance molecule (RGM) protein
|
JP5234666B2
(ja)
*
|
2009-12-11 |
2013-07-10 |
国立大学法人大阪大学 |
乾癬の判定のための測定方法
|
WO2011072336A1
(en)
*
|
2009-12-18 |
2011-06-23 |
The University Of Sydney |
Antiviral agents
|
WO2011079185A1
(en)
*
|
2009-12-23 |
2011-06-30 |
Genentech, Inc. |
Anti-bv8 antibodies and uses thereof
|
JP6012473B2
(ja)
|
2010-01-11 |
2016-10-25 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
抗cd200抗体を用いたヒトの処置における免疫調節効果のバイオマーカー
|
PT2666872T
(pt)
*
|
2010-02-05 |
2016-07-08 |
Astute Medical Inc |
Processos e composições para o diagnóstico e o prognóstico de lesões renais e de insuficiência renal
|
CN105037543B
(zh)
|
2010-03-02 |
2020-11-03 |
Abbvie 公司 |
治疗性dll4结合蛋白
|
CN102781962B
(zh)
|
2010-03-03 |
2014-12-10 |
阿布林克斯公司 |
双互补位A-β结合多肽
|
US8629106B2
(en)
*
|
2010-03-16 |
2014-01-14 |
Janssen Biotech, Inc. |
Affinity peptides toward BMP-2
|
ES2717883T3
(es)
|
2010-03-25 |
2019-06-26 |
Ucb Biopharma Sprl |
Moléculas de DVD-LG estabilizadas con disulfuro
|
AR080794A1
(es)
|
2010-03-26 |
2012-05-09 |
Hoffmann La Roche |
Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
|
TW201138821A
(en)
|
2010-03-26 |
2011-11-16 |
Roche Glycart Ag |
Bispecific antibodies
|
KR20210010942A
(ko)
|
2010-03-31 |
2021-01-28 |
아블렉시스, 엘엘씨 |
키메라 항체의 제조를 위한 비-인간 동물의 유전적 조작
|
RU2630663C9
(ru)
*
|
2010-04-15 |
2017-11-29 |
Проджиникс Фармасьютикалс, Инк. |
Антитела для лечения ассоциированных с clostridium difficile инфекции и заболеваний
|
SG185383A1
(en)
|
2010-04-30 |
2012-12-28 |
Alexion Pharma Inc |
Anti-c5a antibodies and methods for using the antibodies
|
BR112012028306A2
(pt)
|
2010-05-06 |
2020-11-03 |
Novartis Ag |
anticorpos para proteína 6 relacionada com lipoproteína de baixa densidade (lrp6) e seus fragmentos, seu uso, ácidos nucléicos, vetores, bem como composições farmacêuticas e combinações
|
AU2011249782B2
(en)
|
2010-05-06 |
2014-10-02 |
Novartis Ag |
Compositions and methods of use for therapeutic low density lipoprotein - related protein 6 (LRP6) multivalent antibodies
|
LT2571532T
(lt)
|
2010-05-14 |
2017-08-10 |
Abbvie Inc. |
Il-1 surišantys baltymai
|
EP2585110A4
(en)
|
2010-06-22 |
2014-01-22 |
Univ Colorado Regents |
ANTIBODIES AGAINST THE C3D FRAGMENT OF COMPONENT COMPONENT 3
|
WO2012009705A1
(en)
|
2010-07-15 |
2012-01-19 |
Zyngenia, Inc. |
Ang-2 binding complexes and uses thereof
|
AR082461A1
(es)
*
|
2010-08-03 |
2012-12-12 |
Abbott Lab |
Inmunoglobulinas con dominio variable dual y usos de las mismas
|
AU2014246410B2
(en)
*
|
2010-08-03 |
2016-06-16 |
Abbvie Inc. |
Dual variable domain immunoglobulins and uses thereof
|
EP2603525A1
(en)
|
2010-08-13 |
2013-06-19 |
F.Hoffmann-La Roche Ag |
Antibodies to il-1beta and il-18, for treatment of disease
|
MX340556B
(es)
|
2010-08-24 |
2016-07-14 |
Roche Glycart Ag |
Anticuerpos biespecificos activables.
|
JP5758004B2
(ja)
|
2010-08-24 |
2015-08-05 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
ジスルフィドによって安定化されたFv断片を含む二重特異性抗体
|
KR20130139884A
(ko)
|
2010-08-26 |
2013-12-23 |
애브비 인코포레이티드 |
이원 가변 도메인 면역글로불린 및 이의 용도
|
RU2551963C2
(ru)
|
2010-09-09 |
2015-06-10 |
Пфайзер Инк. |
Молекулы, связывающиеся с 4-1вв
|
CN101926998B
(zh)
*
|
2010-09-10 |
2013-09-04 |
中国科学院水生生物研究所 |
肾上腺素受体激动剂诱导胚胎型珠蛋白表达及其用途
|
WO2012057765A1
(en)
*
|
2010-10-28 |
2012-05-03 |
The Board Of Regents Of The University Of Texas System |
Recombinant anti-cd19 monoclonal antibodies
|
WO2012062713A1
(en)
|
2010-11-08 |
2012-05-18 |
Novartis Ag |
Cxcr2 binding polypeptides
|
US20120121576A1
(en)
|
2010-11-08 |
2012-05-17 |
Jasbir Seehra |
Actriia binding agents and uses thereof
|
KR20130121886A
(ko)
|
2010-11-24 |
2013-11-06 |
글락소 그룹 리미티드 |
Hgf를 표적으로 하는 다중특이적 항원 결합 단백질
|
WO2012088094A2
(en)
*
|
2010-12-21 |
2012-06-28 |
Abbott Laboratories |
Il-1 binding proteins
|
CA2821976A1
(en)
*
|
2010-12-21 |
2012-09-13 |
Abbvie Inc. |
Il-1 -alpha and -beta bispecific dual variable domain immunoglobulins and their use
|
EP2654792A4
(en)
*
|
2010-12-22 |
2016-05-11 |
Abbvie Inc |
HALF IMMUNOGLOBULIN BINDING PROTEINS AND USES THEREOF
|
WO2012085111A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
JP2014506132A
(ja)
*
|
2011-01-07 |
2014-03-13 |
アッヴィ・インコーポレイテッド |
抗il−12/il−23抗体およびその使用
|
CA2824719C
(en)
*
|
2011-01-19 |
2020-06-02 |
Cantargia Ab |
Anti-il1rap antibodies and their use for treating solid tumours
|
JP6150734B2
(ja)
|
2011-02-03 |
2017-06-21 |
アレクシオン ファーマシューティカルズ, インコーポレイテッド |
同種移植片の生存を長期化するための抗cd200抗体の使用
|
BR112013020259A2
(pt)
*
|
2011-02-08 |
2018-05-15 |
Abbvie Inc |
tratamento de osteoartrite e dores
|
CN102188707B
(zh)
*
|
2011-02-25 |
2015-08-05 |
中国医学科学院基础医学研究所 |
Il-17抑制剂在制备治疗流感的药物中的用途
|
CN103502271B
(zh)
|
2011-02-28 |
2016-10-26 |
霍夫曼-拉罗奇有限公司 |
抗原结合蛋白
|
CA2824824A1
(en)
|
2011-02-28 |
2012-09-07 |
F. Hoffmann-La Roche Ag |
Monovalent antigen binding proteins
|
MX2013010011A
(es)
|
2011-03-01 |
2014-10-24 |
Amgen Inc |
Agentes de unión biespecífica.
|
CN102757503A
(zh)
*
|
2011-04-28 |
2012-10-31 |
中国人民解放军第二军医大学 |
人前列腺凋亡反应蛋白4与凋亡素2配体融合蛋白的制法和用途
|
CN106432506A
(zh)
|
2011-05-24 |
2017-02-22 |
泽恩格尼亚股份有限公司 |
多价和单价多特异性复合物及其用途
|
CN102253220B
(zh)
*
|
2011-06-07 |
2014-04-09 |
复旦大学附属中山医院 |
用于诊断慢性阻塞性肺病急性加重期的试剂盒
|
MX349886B
(es)
|
2011-06-10 |
2017-08-17 |
Medimmune Llc |
Moleculas de union anti-pseudomonas lectina pisum satinum (psl) y usos de las mismas.
|
CN102268089A
(zh)
|
2011-07-05 |
2011-12-07 |
上海交通大学 |
Agr2阻断抗体及其用途
|
DK2739748T3
(da)
*
|
2011-08-05 |
2019-06-24 |
Univ Aix Marseille |
Il22ra2-gen med fibrosefølsomhed og anvendelser deraf
|
JP6159724B2
(ja)
|
2011-08-23 |
2017-07-05 |
ロシュ グリクアート アーゲー |
T細胞活性化抗原に対して特異的な二重特異性抗体及び腫瘍抗原および使用方法
|
ES2857734T3
(es)
*
|
2011-08-23 |
2021-09-29 |
Roche Glycart Ag |
Moléculas de unión a antígeno activadoras de linfocitos T biespecíficas
|
MX2014002996A
(es)
|
2011-09-23 |
2014-05-28 |
Roche Glycart Ag |
Anticuerpos anti - egfr/anti - igf-1r bisespecificos.
|
TW201323440A
(zh)
|
2011-10-24 |
2013-06-16 |
Abbvie Inc |
抗骨硬化素(sclerostin)之免疫結合物
|
ES2666856T3
(es)
|
2011-11-04 |
2018-05-08 |
Novartis Ag |
Proteína 6 relacionada con lipoproteínas de baja densidad (LRP6) - constructos extensores de la vida media
|
HUE050985T2
(hu)
|
2011-11-07 |
2021-01-28 |
Medimmune Ltd |
Pseudomonas PSL és PCRV elleni kötõmolekulát alkalmazó kombinációs terápiák
|
EP2776061B1
(en)
*
|
2011-11-07 |
2019-08-14 |
MedImmune, LLC |
Multispecific and multivalent binding proteins and uses thereof
|
EP2776451B1
(en)
*
|
2011-11-11 |
2018-07-18 |
Fred Hutchinson Cancer Research Center |
Cyclin a1-targeted t-cell immunotherapy for cancer
|
AP2014007571A0
(en)
*
|
2011-11-16 |
2014-04-30 |
Boehringer Ingelheim Int |
Anti IL-36R antibodies
|
CA2855840C
(en)
|
2011-12-14 |
2023-08-29 |
AbbVie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
EP2791175A2
(en)
|
2011-12-14 |
2014-10-22 |
Abbvie Deutschland GmbH & Co. KG |
Composition and method for the diagnosis and treatment of iron-related disorders
|
CA2861610A1
(en)
*
|
2011-12-30 |
2013-07-04 |
Abbvie Inc. |
Dual specific binding proteins directed against il-13 and/or il-17
|
CN104245733A
(zh)
*
|
2011-12-30 |
2014-12-24 |
艾伯维公司 |
针对受体的双重可变结构域免疫球蛋白
|
SG10202006762PA
(en)
|
2012-01-27 |
2020-08-28 |
Abbvie Deutschland |
Composition and method for diagnosis and treatment of diseases associated with neurite degeneration
|
MX2014009565A
(es)
|
2012-02-10 |
2014-11-10 |
Genentech Inc |
Anticuerpos monocatenarios y otros heteromultimeros.
|
AU2013226340B2
(en)
*
|
2012-02-27 |
2017-06-22 |
Ablynx N.V. |
CX3CR1-binding polypeptides
|
GB2502127A
(en)
|
2012-05-17 |
2013-11-20 |
Kymab Ltd |
Multivalent antibodies and in vivo methods for their production
|
SG11201406238UA
(en)
|
2012-04-05 |
2014-10-30 |
Hoffmann La Roche |
Bispecific antibodies against human tweak and human il17 and uses thereof
|
KR102142508B1
(ko)
|
2012-04-06 |
2020-08-10 |
오메로스 코포레이션 |
발작성 야간혈색뇨증의 치료를 위해 masp-1, masp-2 및/또는 masp-3를 억제하는 조성물 및 방법
|
AR090626A1
(es)
*
|
2012-04-20 |
2014-11-26 |
Lilly Co Eli |
Anticuerpos anti-baff-anti-il-17 biespecificos
|
US9062120B2
(en)
|
2012-05-02 |
2015-06-23 |
Janssen Biotech, Inc. |
Binding proteins having tethered light chains
|
US9328174B2
(en)
|
2012-05-09 |
2016-05-03 |
Novartis Ag |
Chemokine receptor binding polypeptides
|
GB201208370D0
(en)
|
2012-05-14 |
2012-06-27 |
Ucb Pharma Sa |
Antibodies
|
RS61755B1
(sr)
|
2012-06-18 |
2021-05-31 |
Omeros Corp |
Kompozicije i postupci za inhibiciju masp-1 i/ili masp-2 i/ili masp-3 za tretman različitih bolesti i poremećaja
|
WO2014001325A1
(en)
|
2012-06-27 |
2014-01-03 |
F. Hoffmann-La Roche Ag |
Method for making antibody fc-region conjugates comprising at least one binding entity that specifically binds to a target and uses thereof
|
BR112014032193A2
(pt)
|
2012-06-27 |
2017-06-27 |
Hoffmann La Roche |
métodos de produção de anticorpos biespecíficos e de determinação de combinação, anticorpo biespecífico, formulação e uso de anticorpo biespecífico
|
CN107082810B
(zh)
|
2012-07-04 |
2020-12-25 |
弗·哈夫曼-拉罗切有限公司 |
抗茶碱抗体及使用方法
|
KR102090849B1
(ko)
|
2012-07-04 |
2020-03-19 |
에프. 호프만-라 로슈 아게 |
공유 결합된 항원-항체 접합체
|
JP6247287B2
(ja)
|
2012-07-04 |
2017-12-13 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
抗ビオチン抗体および使用方法
|
UY34905A
(es)
|
2012-07-12 |
2014-01-31 |
Abbvie Inc |
Proteínas de unión a il-1
|
EP3495387B1
(en)
|
2012-07-13 |
2021-09-01 |
Roche Glycart AG |
Bispecific anti-vegf/anti-ang-2 antibodies and their use in the treatment of ocular vascular diseases
|
JOP20200308A1
(ar)
|
2012-09-07 |
2017-06-16 |
Novartis Ag |
جزيئات إرتباط il-18
|
JOP20200236A1
(ar)
*
|
2012-09-21 |
2017-06-16 |
Regeneron Pharma |
الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
|
CA2879768A1
(en)
|
2012-10-08 |
2014-04-17 |
Roche Glycart Ag |
Fc-free antibodies comprising two fab-fragments and methods of use
|
KR20210111353A
(ko)
|
2012-11-01 |
2021-09-10 |
애브비 인코포레이티드 |
항-vegf/dll4 이원 가변 도메인 면역글로불린 및 이의 용도
|
CA2891686A1
(en)
|
2012-12-18 |
2014-06-26 |
Novartis Ag |
Compositions and methods that utilize a peptide tag that binds to hyaluronan
|
JO3519B1
(ar)
*
|
2013-01-25 |
2020-07-05 |
Amgen Inc |
تركيبات أجسام مضادة لأجل cdh19 و cd3
|
CN103103197A
(zh)
*
|
2013-01-30 |
2013-05-15 |
百奇生物科技(苏州)有限公司 |
抗cd138单克隆抗体可变区序列及其制备方法和应用
|
EP3744736A1
(en)
|
2013-02-20 |
2020-12-02 |
Novartis AG |
Effective targeting of primary human leukemia using anti-cd123 chimeric antigen receptor engineered t cells
|
DK2958943T3
(da)
|
2013-02-20 |
2019-12-09 |
Univ Pennsylvania |
Behandling af cancer ved anvendelse af humaniseret anti-EGFRvIII kimær antigenreceptor
|
EP2961773B1
(en)
|
2013-02-26 |
2019-03-20 |
Roche Glycart AG |
Bispecific t cell activating antigen binding molecules
|
EP3708584A1
(en)
|
2013-02-26 |
2020-09-16 |
Roche Glycart AG |
Bispecific t cell activating antigen binding molecules
|
JOP20140087B1
(ar)
|
2013-03-13 |
2021-08-17 |
Amgen Inc |
بروتينات مخصصة ل baff و b7rp1 وإستخداماتها
|
US9458246B2
(en)
|
2013-03-13 |
2016-10-04 |
Amgen Inc. |
Proteins specific for BAFF and B7RP1
|
JP2016522793A
(ja)
*
|
2013-03-15 |
2016-08-04 |
アッヴィ・インコーポレイテッド |
IL−1βおよび/またはIL−17に対して指向された二重特異的結合タンパク質
|
WO2014145252A2
(en)
|
2013-03-15 |
2014-09-18 |
Milone Michael C |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
EP2970484B2
(en)
|
2013-03-15 |
2022-09-21 |
Amgen Inc. |
Heterodimeric bispecific antibodies
|
EP2968541A4
(en)
|
2013-03-15 |
2017-02-08 |
Zyngenia, Inc. |
Multivalent and monovalent multispecific complexes and their uses
|
US9469686B2
(en)
|
2013-03-15 |
2016-10-18 |
Abbott Laboratories |
Anti-GP73 monoclonal antibodies and methods of obtaining the same
|
UY35468A
(es)
|
2013-03-16 |
2014-10-31 |
Novartis Ag |
Tratamiento de cáncer utilizando un receptor quimérico de antígeno anti-cd19
|
CA2913118A1
(en)
*
|
2013-05-22 |
2014-11-27 |
Metabolic Engineering Laboratories Co., Ltd. |
Anti-tnf-.alpha./cxcl10 double-targeting antibody and use thereof
|
NZ715896A
(en)
|
2013-07-05 |
2022-02-25 |
Genmab As |
Humanized or chimeric cd3 antibodies
|
CN104341504B
(zh)
|
2013-08-06 |
2017-10-24 |
百奥泰生物科技(广州)有限公司 |
双特异性抗体
|
CN104231086B
(zh)
*
|
2013-08-27 |
2019-12-13 |
北京韩美药品有限公司 |
双功能融合蛋白及其制备方法和用途
|
CN103467605B
(zh)
*
|
2013-09-05 |
2015-02-04 |
武汉友芝友生物制药有限公司 |
一种cd3抗原及其制备方法和用途
|
WO2015039212A1
(en)
|
2013-09-17 |
2015-03-26 |
University Health Network (Uhn): Technology Development And Commercialization |
Agents directed against a cis rgma/neogenin interaction or lipid rafts and use of the same in methods of treatment
|
EP3049442A4
(en)
|
2013-09-26 |
2017-06-28 |
Costim Pharmaceuticals Inc. |
Methods for treating hematologic cancers
|
JP6422956B2
(ja)
|
2013-10-11 |
2018-11-14 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
多重特異性ドメイン交換共通可変軽鎖抗体
|
CN104592390B
(zh)
*
|
2013-10-30 |
2017-11-10 |
上海张江生物技术有限公司 |
一类双特异重组抗HBsAg抗体、其制备方法及用途
|
GB201320066D0
(en)
|
2013-11-13 |
2013-12-25 |
Ucb Pharma Sa |
Biological products
|
ES2918501T3
(es)
|
2013-12-19 |
2022-07-18 |
Novartis Ag |
Receptores de antígenos quiméricos de mesotelina humana y usos de los mismos
|
CR20160270A
(es)
|
2013-12-20 |
2016-09-05 |
Hoffmann La Roche |
ANTICUERPOS ANTI-TAU (pS422) HUMANIZADOS Y MÉTODOS DE UTILIZACIÓN
|
WO2015090229A1
(en)
|
2013-12-20 |
2015-06-25 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
MX2016008189A
(es)
|
2014-01-03 |
2016-09-29 |
Hoffmann La Roche |
Conjugados helicoidales-anticuerpo anti-helicoidal unidos covalentemente y usos de los mismos.
|
US10561737B2
(en)
|
2014-01-03 |
2020-02-18 |
Hoffmann-La Roche Inc. |
Bispecific anti-hapten/anti-blood brain barrier receptor antibodies, complexes thereof and their use as blood brain barrier shuttles
|
MX2016008191A
(es)
|
2014-01-03 |
2017-11-16 |
Hoffmann La Roche |
Conjugados de toxina polipeptidica-anticuerpo unidos covalentemente.
|
CR20160316A
(es)
|
2014-01-10 |
2016-09-19 |
Glaxosmithkline Intellectual Property (No 2) Ltd |
Compuestos derivados de hidroxiformamida y usos del mismo
|
EP4303229A3
(en)
|
2014-01-21 |
2024-04-17 |
Novartis AG |
Enhanced antigen presenting ability of car t cells by co-introduction of costimulatory molecules
|
JOP20200094A1
(ar)
|
2014-01-24 |
2017-06-16 |
Dana Farber Cancer Inst Inc |
جزيئات جسم مضاد لـ pd-1 واستخداماتها
|
KR20160113268A
(ko)
*
|
2014-01-28 |
2016-09-28 |
베이징 한미 파마슈티컬 컴퍼니 리미티드 |
이기능 융합단백질,이의 제조방법 및 용도
|
JOP20200096A1
(ar)
|
2014-01-31 |
2017-06-16 |
Children’S Medical Center Corp |
جزيئات جسم مضاد لـ tim-3 واستخداماتها
|
JP6712235B2
(ja)
*
|
2014-02-24 |
2020-06-17 |
イミューンファルマ エッセ.エッレ.エッレ. |
肺癌のためのバイオマーカー、その診断方法、およびキット
|
WO2015142675A2
(en)
|
2014-03-15 |
2015-09-24 |
Novartis Ag |
Treatment of cancer using chimeric antigen receptor
|
WO2015142661A1
(en)
|
2014-03-15 |
2015-09-24 |
Novartis Ag |
Regulatable chimeric antigen receptor
|
TWI701042B
(zh)
|
2014-03-19 |
2020-08-11 |
美商再生元醫藥公司 |
用於腫瘤治療之方法及抗體組成物
|
US10308712B2
(en)
|
2014-03-27 |
2019-06-04 |
Bird Rock Bio, Inc. |
Antibodies that bind human cannabinoid 1 (CB1) receptor
|
DK3129470T3
(da)
|
2014-04-07 |
2021-07-05 |
Novartis Ag |
Behandling af cancer ved anvendelse af anti-CD19-kimær antigenreceptor
|
NZ726514A
(en)
|
2014-05-29 |
2019-01-25 |
Macrogenics Inc |
Tri-specific binding molecules and methods of use thereof
|
AU2015274277B2
(en)
|
2014-06-13 |
2021-03-18 |
Acceleron Pharma, Inc. |
Methods and compositions for treating ulcers
|
EP3160990A2
(en)
|
2014-06-25 |
2017-05-03 |
Novartis AG |
Compositions and methods for long acting proteins
|
US20170327553A1
(en)
|
2014-06-25 |
2017-11-16 |
Novartis Ag |
Compositions and methods for long acting proteins
|
US20170291939A1
(en)
|
2014-06-25 |
2017-10-12 |
Novartis Ag |
Antibodies specific for il-17a fused to hyaluronan binding peptide tags
|
AR100978A1
(es)
|
2014-06-26 |
2016-11-16 |
Hoffmann La Roche |
LANZADERAS CEREBRALES DE ANTICUERPO HUMANIZADO ANTI-Tau(pS422) Y USOS DE LAS MISMAS
|
KR102594343B1
(ko)
|
2014-07-21 |
2023-10-26 |
노파르티스 아게 |
Cd33 키메라 항원 수용체를 사용한 암의 치료
|
US11542488B2
(en)
|
2014-07-21 |
2023-01-03 |
Novartis Ag |
Sortase synthesized chimeric antigen receptors
|
KR102612313B1
(ko)
|
2014-07-21 |
2023-12-12 |
노파르티스 아게 |
인간화 항-bcma 키메라 항원 수용체를 사용한 암의 치료
|
JP2017528433A
(ja)
|
2014-07-21 |
2017-09-28 |
ノバルティス アーゲー |
低い免疫増強用量のmTOR阻害剤とCARの組み合わせ
|
EP4205749A1
(en)
|
2014-07-31 |
2023-07-05 |
Novartis AG |
Subset-optimized chimeric antigen receptor-containing cells
|
CA2951599A1
(en)
|
2014-08-04 |
2016-02-11 |
F. Hoffmann-La Roche Ag |
Bispecific t cell activating antigen binding molecules
|
NZ728425A
(en)
|
2014-08-07 |
2022-05-27 |
Novartis Ag |
Angiopoietin-like 4 antibodies and methods of use
|
US9988443B2
(en)
|
2014-08-07 |
2018-06-05 |
Novartis Ag |
Angiopoetin-like 4 (ANGPTL4) antibodies and methods of use
|
EP3180359A1
(en)
|
2014-08-14 |
2017-06-21 |
Novartis AG |
Treatment of cancer using gfr alpha-4 chimeric antigen receptor
|
SG11201700770PA
(en)
|
2014-08-19 |
2017-03-30 |
Novartis Ag |
Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment
|
GB201414823D0
(en)
|
2014-08-20 |
2014-10-01 |
Argen X Bv |
Multispecific antibodies
|
CN107206071A
(zh)
|
2014-09-13 |
2017-09-26 |
诺华股份有限公司 |
Alk抑制剂的联合疗法
|
AU2015317608B2
(en)
|
2014-09-17 |
2021-03-11 |
Novartis Ag |
Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy
|
AU2015324924B2
(en)
|
2014-10-01 |
2021-07-01 |
Medimmune, Llc |
Method of conjugating a polypeptide
|
DK3221359T3
(da)
|
2014-11-17 |
2020-06-22 |
Regeneron Pharma |
Fremgangsmåder til tumorbehandling ved anvendelse af CD3XCD20-bispecifikt antistof
|
DK3220952T3
(da)
|
2014-11-17 |
2021-07-19 |
Csl Ltd |
Fremgangsmåde til behandling eller forebyggelse af slagtilfælde
|
DK3221355T3
(da)
|
2014-11-20 |
2020-12-07 |
Hoffmann La Roche |
Kombinationsbehandling med T-celleaktiverende bispecifikke antigenbindende molekyler CD3 og folatreceptor 1 (FolR1) samt PD-1-aksebindende antagonister
|
CN105669867A
(zh)
*
|
2014-11-21 |
2016-06-15 |
上海中信国健药业股份有限公司 |
抗gitr/ctla-4双特异性抗体及其制备方法和用途
|
WO2016090034A2
(en)
|
2014-12-03 |
2016-06-09 |
Novartis Ag |
Methods for b cell preconditioning in car therapy
|
JP6721590B2
(ja)
|
2014-12-03 |
2020-07-15 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
多重特異性抗体
|
US10982008B2
(en)
*
|
2014-12-05 |
2021-04-20 |
Merck Patent Gmbh |
Domain-exchanged antibody
|
CA2969704C
(en)
|
2014-12-05 |
2023-05-02 |
City Of Hope |
Cs1 targeted chimeric antigen receptor-modified t cells
|
WO2016094881A2
(en)
|
2014-12-11 |
2016-06-16 |
Abbvie Inc. |
Lrp-8 binding proteins
|
US20160168237A1
(en)
|
2014-12-12 |
2016-06-16 |
Alexion Pharmaceuticals, Inc. |
Method for treating a complement mediated disorder caused by an infectious agent in a patient
|
EP3240803B1
(en)
|
2014-12-29 |
2021-11-24 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
WO2016118921A1
(en)
|
2015-01-24 |
2016-07-28 |
Abbvie, Inc. |
Compositions and methods for treating psoriatic arthritis
|
AU2016212162A1
(en)
|
2015-01-26 |
2017-07-13 |
Cellectis |
T cell receptor knock out engineered immune cells, endowed with chimeric antigen receptors binding to CD123 for the treatment of relapsed/refractory acute myeloid lymphoma or blastic plasmacytoid dendritic cell neoplasm
|
JP6602875B2
(ja)
|
2015-01-26 |
2019-11-06 |
マクロジェニクス,インコーポレーテッド |
Dr5結合ドメインを含む多価分子
|
US11161907B2
(en)
|
2015-02-02 |
2021-11-02 |
Novartis Ag |
Car-expressing cells against multiple tumor antigens and uses thereof
|
CN105988009B
(zh)
*
|
2015-02-28 |
2018-03-13 |
复旦大学附属华山医院 |
Netrin‑4在制备检测胃癌及预后标志物的制剂中的用途
|
EP3070103A1
(en)
*
|
2015-03-19 |
2016-09-21 |
Institut Hospitalier Universitaire De Strasbourg |
Anti-Claudin 1 monoclonal antibodies for the prevention and treatment of hepatocellular carcinoma
|
US10273305B2
(en)
*
|
2015-04-02 |
2019-04-30 |
Ablynx N.V. |
Bispecific CXCR4-CD4 polypeptides with potent anti-HIV activity
|
KR20170134642A
(ko)
|
2015-04-08 |
2017-12-06 |
노파르티스 아게 |
Cd20 요법, cd22 요법, 및 cd19 키메라 항원 수용체 (car) - 발현 세포와의 조합 요법
|
CN108473957A
(zh)
|
2015-04-17 |
2018-08-31 |
诺华股份有限公司 |
改善嵌合抗原受体表达细胞的功效和扩增的方法
|
EP3286211A1
(en)
|
2015-04-23 |
2018-02-28 |
Novartis AG |
Treatment of cancer using chimeric antigen receptor and protein kinase a blocker
|
CA2982427A1
(en)
|
2015-04-30 |
2016-11-03 |
President And Fellows Of Harvard College |
Anti-ap2 antibodies and antigen binding agents to treat metabolic disorders
|
US10989716B2
(en)
|
2015-05-01 |
2021-04-27 |
The University Of British Columbia |
Biomarkers for the detection of acute rejection in heart transplantation
|
GB201508180D0
(en)
|
2015-05-13 |
2015-06-24 |
Ucb Biopharma Sprl |
Antibodies
|
CN104987421A
(zh)
*
|
2015-05-13 |
2015-10-21 |
北京比洋生物技术有限公司 |
抗ctla-4和pd-1的双重可变结构域免疫球蛋白
|
FI3298033T4
(fi)
|
2015-05-18 |
2023-09-22 |
Tcr2 Therapeutics Inc |
Koostumuksia ja lääkinnällisiä käyttöjä fuusioproteiineja käyttävälle tcr:n uudelleenohjelmoinnille
|
EP3297672B1
(en)
|
2015-05-21 |
2021-09-01 |
Harpoon Therapeutics, Inc. |
Trispecific binding proteins and methods of use
|
US10682391B2
(en)
|
2015-06-04 |
2020-06-16 |
Ospedale San Raffaele Srl |
Inhibitors of IGFBP3 binding to TMEM219 for treatment of intestinal diseases
|
NZ738389A
(en)
|
2015-06-04 |
2019-02-22 |
Ospedale San Raffaele Srl |
Inhibitor of igfbp3/tmem219 axis and diabetes
|
TWI773646B
(zh)
|
2015-06-08 |
2022-08-11 |
美商宏觀基因股份有限公司 |
結合lag-3的分子和其使用方法
|
TWI737614B
(zh)
|
2015-06-11 |
2021-09-01 |
博錸生技股份有限公司 |
已編碼微載體及其製造方法以及用以進行多工分析之包含該等已編碼微載體之套件
|
TW201710286A
(zh)
|
2015-06-15 |
2017-03-16 |
艾伯維有限公司 |
抗vegf、pdgf及/或其受體之結合蛋白
|
CN113929779A
(zh)
|
2015-06-24 |
2022-01-14 |
豪夫迈·罗氏有限公司 |
人源化的抗-Tau(pS422)抗体和使用方法
|
JP6630426B2
(ja)
|
2015-07-06 |
2020-01-15 |
ユーシービー バイオファルマ エスピーアールエル |
Tau結合抗体
|
TN2017000543A1
(en)
|
2015-07-06 |
2019-04-12 |
Ucb Biopharma Sprl |
Tau-binding antibodies
|
WO2017015427A1
(en)
|
2015-07-21 |
2017-01-26 |
Novartis Ag |
Methods for improving the efficacy and expansion of immune cells
|
HUE056201T2
(hu)
|
2015-07-30 |
2022-02-28 |
Macrogenics Inc |
PD-1-hez kötõdõ molekulák és alkalmazásukra szolgáló eljárások
|
EP3331913A1
(en)
|
2015-08-07 |
2018-06-13 |
Novartis AG |
Treatment of cancer using chimeric cd3 receptor proteins
|
CN108350070B
(zh)
|
2015-09-09 |
2022-01-28 |
诺华股份有限公司 |
胸腺基质淋巴细胞生成素(tslp)-结合分子及该分子的使用方法
|
TN2018000076A1
(en)
|
2015-09-09 |
2019-07-08 |
Novartis Ag |
Thymic stromal lymphopoietin (tslp)-binding molecules and methods of using the molecules
|
EP4324476A3
(en)
|
2015-09-11 |
2024-05-01 |
AbbVie Inc. |
Methods for treating relapsing forms of multiple sclerosis
|
WO2017044811A1
(en)
|
2015-09-11 |
2017-03-16 |
Bruce Andrien |
Recombinant glycosylated eculizumab and eculizumab variants
|
ES2878008T3
(es)
*
|
2015-09-17 |
2021-11-18 |
Scripps Research Inst |
Inmunoconjugados de dominio variable dual y usos de los mismos
|
CA2999138C
(en)
|
2015-09-21 |
2024-05-21 |
Aptevo Research And Development Llc |
Cd3 binding polypeptides
|
EP3352800B1
(en)
*
|
2015-09-24 |
2022-01-05 |
The University of North Carolina at Chapel Hill |
Methods and compositions for reducing metastases
|
AU2016330471B2
(en)
|
2015-09-30 |
2022-09-29 |
Bird Rock Bio, Inc. |
Antibodies that bind human cannabinoid 1 (CB1) receptor
|
AR106188A1
(es)
|
2015-10-01 |
2017-12-20 |
Hoffmann La Roche |
Anticuerpos anti-cd19 humano humanizados y métodos de utilización
|
CR20180162A
(es)
|
2015-10-02 |
2018-05-25 |
Hoffmann La Roche |
Moléculas biespecíficas de unión a antígeno activadoras de células t
|
EP3359566A1
(en)
|
2015-10-07 |
2018-08-15 |
Alexion Pharmaceuticals, Inc. |
A method for treating age-related macular degeneration in a patient
|
AU2016355568A1
(en)
*
|
2015-11-18 |
2018-06-21 |
Merck Sharp & Dohme Llc |
PD1/CTLA4 Binders
|
US10711282B2
(en)
|
2015-11-23 |
2020-07-14 |
Novartis Ag |
Optimized lentiviral transfer vectors and uses thereof
|
CN115920030A
(zh)
|
2015-12-09 |
2023-04-07 |
豪夫迈·罗氏有限公司 |
Ii型抗cd20抗体用于降低抗药物抗体形成
|
TWI758267B
(zh)
|
2015-12-14 |
2022-03-21 |
美商宏觀基因股份有限公司 |
對於pd-1和ctla-4具有免疫反應性的雙特異性分子及其使用方法
|
GB201522394D0
(en)
|
2015-12-18 |
2016-02-03 |
Ucb Biopharma Sprl |
Antibodies
|
CN106918699B
(zh)
*
|
2015-12-25 |
2018-07-06 |
广州瑞博奥生物科技有限公司 |
一种检测肾癌标记物的抗体芯片试剂盒
|
WO2017114497A1
(en)
|
2015-12-30 |
2017-07-06 |
Novartis Ag |
Immune effector cell therapies with enhanced efficacy
|
CN106661117B
(zh)
*
|
2015-12-30 |
2020-11-17 |
深圳先进技术研究院 |
IgG杂合型抗TNFα和IL-17A双特异性抗体
|
CA3006529A1
(en)
|
2016-01-08 |
2017-07-13 |
F. Hoffmann-La Roche Ag |
Methods of treating cea-positive cancers using pd-1 axis binding antagonists and anti-cea/anti-cd3 bispecific antibodies
|
WO2017123673A2
(en)
|
2016-01-11 |
2017-07-20 |
Inhibrx Lp |
Multivalent and multispecific ox40-binding fusion proteins
|
SG11201805532XA
(en)
|
2016-01-11 |
2018-07-30 |
Inhibrx Inc |
Multivalent and multispecific 41bb-binding fusion proteins
|
WO2017125897A1
(en)
|
2016-01-21 |
2017-07-27 |
Novartis Ag |
Multispecific molecules targeting cll-1
|
CN105481981B
(zh)
*
|
2016-01-27 |
2019-03-19 |
中国人民解放军第二军医大学 |
靶向vegf双特异性抗体及其用途
|
RU2018128784A
(ru)
|
2016-01-27 |
2020-02-27 |
МЕДИММЬЮН, ЭлЭлСи |
Способы получения антител с заданным профилем гликозилирования
|
US20170233472A1
(en)
|
2016-02-17 |
2017-08-17 |
Macrogenics, Inc. |
ROR1-Binding Molecules, and Methods of Use Thereof
|
EP3423482A1
(en)
|
2016-03-04 |
2019-01-09 |
Novartis AG |
Cells expressing multiple chimeric antigen receptor (car) molecules and uses therefore
|
DK3433280T3
(da)
|
2016-03-22 |
2023-06-19 |
Hoffmann La Roche |
Protease-aktiverede T-celle-bispecifikke molekyler
|
WO2017165683A1
(en)
|
2016-03-23 |
2017-09-28 |
Novartis Ag |
Cell secreted minibodies and uses thereof
|
US20190112380A1
(en)
|
2016-03-29 |
2019-04-18 |
University Of Southern California |
Chimeric antigen receptors targeting cancer
|
KR20220133318A
(ko)
|
2016-04-15 |
2022-10-04 |
노파르티스 아게 |
선택적 단백질 발현을 위한 조성물 및 방법
|
KR102514317B1
(ko)
|
2016-04-15 |
2023-03-27 |
마크로제닉스, 인크. |
신규 b7-h3-결합 분자, 그것의 항체 약물 콘쥬게이트 및 그것의 사용 방법
|
CN107347014B
(zh)
*
|
2016-05-04 |
2020-12-18 |
中国移动通信集团广东有限公司 |
一种网络故障检测方法和系统
|
GB201608197D0
(en)
*
|
2016-05-10 |
2016-06-22 |
Ducentis Biotherapeutics Ltd |
Novel proteins
|
US11623958B2
(en)
|
2016-05-20 |
2023-04-11 |
Harpoon Therapeutics, Inc. |
Single chain variable fragment CD3 binding proteins
|
JP7101621B2
(ja)
|
2016-05-20 |
2022-07-15 |
ハープーン セラピューティクス,インク. |
単一ドメイン血清アルブミン結合タンパク質
|
MA45123A
(fr)
|
2016-05-27 |
2019-04-10 |
Agenus Inc |
Anticorps anti-tim-3 et leurs méthodes d'utilisation
|
BR112018074966A2
(pt)
|
2016-06-01 |
2019-03-12 |
AbbVie Deutschland GmbH & Co. KG |
anticorpos antagonísticos anti-molécula de orientação repulsiva a (grma) para tratar lesão na medula espinhal e dor
|
US20210177896A1
(en)
|
2016-06-02 |
2021-06-17 |
Novartis Ag |
Therapeutic regimens for chimeric antigen receptor (car)- expressing cells
|
GB201610198D0
(en)
|
2016-06-10 |
2016-07-27 |
Ucb Biopharma Sprl |
Anti-ige antibodies
|
CN106110426B
(zh)
*
|
2016-07-01 |
2019-01-22 |
翁炳焕 |
艾滋病免疫治疗仪
|
CA3030837A1
(en)
|
2016-07-15 |
2018-01-18 |
Novartis Ag |
Treatment and prevention of cytokine release syndrome using a chimeric antigen receptor in combination with a kinase inhibitor
|
WO2018014260A1
(en)
*
|
2016-07-20 |
2018-01-25 |
Nanjing Legend Biotech Co., Ltd. |
Multispecific antigen binding proteins and methods of use thereof
|
EP3491016A1
(en)
|
2016-07-28 |
2019-06-05 |
Novartis AG |
Combination therapies of chimeric antigen receptors and pd-1 inhibitors
|
JOP20170154B1
(ar)
|
2016-08-01 |
2023-03-28 |
Omeros Corp |
تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
|
RU2019105693A
(ru)
|
2016-08-01 |
2020-09-01 |
Новартис Аг |
Лечение рака с применением химерного антигенного рецептора в комбинации с ингибитором молекулы, способствующей фенотипу m2 макрофага
|
AU2017306432A1
(en)
|
2016-08-02 |
2019-03-21 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
WO2018045110A1
(en)
|
2016-08-30 |
2018-03-08 |
Xencor, Inc. |
Bispecific immunomodulatory antibodies that bind costimulatory and checkpoint receptors
|
WO2018050902A2
(en)
|
2016-09-15 |
2018-03-22 |
Quadrucept Bio Limited |
Multimers, tetramers & octamers
|
CN107868791B
(zh)
*
|
2016-09-26 |
2021-11-23 |
阿思科力(苏州)生物科技有限公司 |
一种加强型Slit2 CAR-T和CAR-NK细胞制备方法和应用
|
PL3519437T3
(pl)
|
2016-09-30 |
2022-01-17 |
F. Hoffmann-La Roche Ag |
Przeciwciała dwuswoiste przeciwko p95HER2
|
JP2019535015A
(ja)
|
2016-10-03 |
2019-12-05 |
アボット・ラボラトリーズAbbott Laboratories |
患者サンプルにおけるgfap状況を評価する改善された方法
|
US10525083B2
(en)
|
2016-10-07 |
2020-01-07 |
Novartis Ag |
Nucleic acid molecules encoding chimeric antigen receptors comprising a CD20 binding domain
|
AU2017341048A1
(en)
|
2016-10-07 |
2019-05-23 |
TCR2 Therapeutics Inc. |
Compositions and methods for T-cell receptors reprogramming using fusion proteins
|
ES2848206T3
(es)
|
2016-10-19 |
2021-08-05 |
Alexion Pharma Inc |
Un método de cuantificar C5 sin unir en una muestra
|
EP3529619B1
(en)
|
2016-10-19 |
2021-06-30 |
Alexion Pharmaceuticals, Inc. |
A method of quantitating unbound c5a in a sample
|
US11851491B2
(en)
|
2016-11-22 |
2023-12-26 |
TCR2 Therapeutics Inc. |
Compositions and methods for TCR reprogramming using fusion proteins
|
BR112019010602A2
(pt)
|
2016-11-23 |
2019-12-17 |
Harpoon Therapeutics Inc |
proteínas trispecíficas para psma e métodos de uso
|
EP3544997A4
(en)
|
2016-11-23 |
2020-07-01 |
Harpoon Therapeutics, Inc. |
PROSTATE SPECIFIC MEMBRANE ANTIGEN BINDING PROTEIN
|
US20180206726A1
(en)
|
2016-12-07 |
2018-07-26 |
Progenity Inc. |
Gastrointestinal tract detection methods, devices and systems
|
US11230610B2
(en)
|
2016-12-09 |
2022-01-25 |
Seagen Inc. |
Bivalent antibodies masked by coiled coils
|
AU2017378406A1
(en)
|
2016-12-14 |
2019-06-13 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunosuppressant
|
WO2018112256A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with an il-1 inhibitor
|
MX2019006864A
(es)
|
2016-12-14 |
2019-10-15 |
Progenity Inc |
Tratamiento de una enfermedad del tracto gastrointestinal con un inhibidor de factor de necrosis tumoral (tnf).
|
AU2017378398B2
(en)
|
2016-12-14 |
2023-02-02 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with a JAK inhibitor and devices
|
US11134889B2
(en)
|
2016-12-14 |
2021-10-05 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a SMAD7 inhibitor
|
WO2018112237A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with an il-6r inhibitor
|
CN117045784A
(zh)
|
2016-12-14 |
2023-11-14 |
比奥拉治疗股份有限公司 |
使用利用可摄入装置释放的il-12/il-23抑制剂治疗胃肠道疾病
|
AU2017376801A1
(en)
|
2016-12-14 |
2019-06-13 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with an integrin inhibitor
|
EP3554344A1
(en)
|
2016-12-14 |
2019-10-23 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a tlr modulator
|
CA3045310A1
(en)
|
2016-12-14 |
2018-06-21 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with a chemokine/chemokine receptor inhibitor
|
WO2018111340A1
(en)
|
2016-12-16 |
2018-06-21 |
Novartis Ag |
Methods for determining potency and proliferative function of chimeric antigen receptor (car)-t cells
|
AR110424A1
(es)
|
2016-12-23 |
2019-03-27 |
Macrogenics Inc |
Moléculas de unión a adam9 y métodos de uso de las mismas
|
EP3574005B1
(en)
|
2017-01-26 |
2021-12-15 |
Novartis AG |
Cd28 compositions and methods for chimeric antigen receptor therapy
|
US20190375815A1
(en)
|
2017-01-31 |
2019-12-12 |
Novartis Ag |
Treatment of cancer using chimeric t cell receptor proteins having multiple specificities
|
US11459394B2
(en)
|
2017-02-24 |
2022-10-04 |
Macrogenics, Inc. |
Bispecific binding molecules that are capable of binding CD137 and tumor antigens, and uses thereof
|
US11535668B2
(en)
|
2017-02-28 |
2022-12-27 |
Harpoon Therapeutics, Inc. |
Inducible monovalent antigen binding protein
|
CN106706930B
(zh)
*
|
2017-02-28 |
2018-11-02 |
扬州诺明哲天医学检验实验室有限公司 |
一种用于帕金森综合症检测的试剂盒
|
CN106596979B
(zh)
*
|
2017-02-28 |
2018-10-09 |
汉氏联合(天津)干细胞研究院有限公司 |
一种用于帕金森综合症检测的试剂盒及其检测方法
|
JP7346300B2
(ja)
|
2017-03-23 |
2023-09-19 |
アボット・ラボラトリーズ |
早期バイオマーカーであるユビキチンカルボキシ末端ヒドロラーゼl1を使用する、ヒト対象における外傷性脳損傷の程度の診断及び決定の一助となるための方法
|
EP3600416B1
(en)
|
2017-03-30 |
2023-06-07 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device
|
US11596670B2
(en)
|
2017-03-30 |
2023-03-07 |
Biora Therapeutics, Inc. |
Treatment of a disease of the gastrointestinal tract with IL-10 or an IL-10 agonist
|
WO2018183941A2
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with live biotherapeutics
|
EP3600249A1
(en)
|
2017-03-30 |
2020-02-05 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a chst15 inhibitor
|
WO2018183932A1
(en)
|
2017-03-30 |
2018-10-04 |
Progenity Inc. |
Treatment of a disease of the gastrointestinal tract with a il-13 inhibitor
|
AU2018250688A1
(en)
|
2017-04-15 |
2019-08-29 |
Abbott Laboratories |
Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury in a human subject using early biomarkers
|
EP3615068A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Bcma-targeting agent, and combination therapy with a gamma secretase inhibitor
|
EP3615055A1
(en)
|
2017-04-28 |
2020-03-04 |
Novartis AG |
Cells expressing a bcma-targeting chimeric antigen receptor, and combination therapy with a gamma secretase inhibitor
|
WO2018200823A1
(en)
|
2017-04-28 |
2018-11-01 |
Abbott Laboratories |
Methods for aiding in the hyperacute diagnosis and determination of traumatic brain injury using early biomarkers on at least two samples from the same human subject
|
EP3621648A4
(en)
|
2017-05-12 |
2021-01-20 |
Harpoon Therapeutics, Inc. |
TRISPECIFIC PROTEINS MSLN AND METHOD OF USE
|
JP7090347B2
(ja)
|
2017-05-12 |
2022-06-24 |
ハープーン セラピューティクス,インク. |
メソテリン結合タンパク質
|
WO2018213335A1
(en)
|
2017-05-16 |
2018-11-22 |
Scalmibio, Inc. |
Activatable antibodies and methods of use thereof
|
AU2018272054A1
(en)
|
2017-05-25 |
2019-09-26 |
Abbott Laboratories |
Methods for aiding in the determination of whether to perform imaging on a human subject who has sustained or may have sustained an injury to the head using early biomarkers
|
AR111963A1
(es)
|
2017-05-26 |
2019-09-04 |
Univ California |
Método y moléculas
|
CN110709704A
(zh)
|
2017-05-30 |
2020-01-17 |
雅培实验室 |
利用心肌肌钙蛋白i辅助诊断和评估人类受试者的轻度创伤性脑损伤的方法
|
WO2018232020A1
(en)
|
2017-06-13 |
2018-12-20 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
WO2018236904A1
(en)
|
2017-06-19 |
2018-12-27 |
Surface Oncology, Inc. |
COMBINATION OF ANTI-CD47 ANTIBODIES AND CELL DEATH INDUCING AGENTS, AND USES THEREOF
|
JP7454945B2
(ja)
|
2017-07-03 |
2024-03-25 |
アボット・ラボラトリーズ |
血液中のユビキチンカルボキシ末端ヒドロラーゼl1レベルを測定するための、改善された方法
|
SG10201913144TA
(en)
|
2017-07-11 |
2020-03-30 |
Compass Therapeutics Llc |
Agonist antibodies that bind human cd137 and uses thereof
|
CN107375904B
(zh)
*
|
2017-08-01 |
2020-11-27 |
无锡市人民医院 |
β-arrestin1在防治色素障碍性皮肤病中的应用
|
JP2020529605A
(ja)
|
2017-08-01 |
2020-10-08 |
コンパス セラピューティクス リミテッド ライアビリティ カンパニー |
濾過およびクロマトグラフィ用ポッドならびにその使用方法
|
WO2019036363A1
(en)
|
2017-08-14 |
2019-02-21 |
Progenity Inc. |
TREATMENT OF GASTROINTESTINAL TRACT DISEASE WITH GLATIRAMER OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF
|
AU2018346955A1
(en)
|
2017-10-13 |
2020-04-30 |
Harpoon Therapeutics, Inc. |
B cell maturation antigen binding proteins
|
CN111630070A
(zh)
|
2017-10-13 |
2020-09-04 |
哈普恩治疗公司 |
三特异性蛋白质及使用方法
|
JP2021501570A
(ja)
|
2017-10-18 |
2021-01-21 |
ノバルティス アーゲー |
選択的タンパク質分解のための組成物及び方法
|
CN111566124A
(zh)
|
2017-10-25 |
2020-08-21 |
诺华股份有限公司 |
制备表达嵌合抗原受体的细胞的方法
|
WO2019089753A2
(en)
|
2017-10-31 |
2019-05-09 |
Compass Therapeutics Llc |
Cd137 antibodies and pd-1 antagonists and uses thereof
|
WO2019090148A2
(en)
|
2017-11-03 |
2019-05-09 |
Rubius Therapeutics, Inc. |
Compositions and methods related to therapeutic cell systems for tumor growth inhibition
|
KR102189893B1
(ko)
*
|
2017-11-15 |
2020-12-11 |
(주)에스엘에스바이오 |
bPAG1에 특이적으로 결합하는 항체 및 이의 용도
|
EP3713961A2
(en)
|
2017-11-20 |
2020-09-30 |
Compass Therapeutics LLC |
Cd137 antibodies and tumor antigen-targeting antibodies and uses thereof
|
BR112020010085A2
(pt)
|
2017-12-09 |
2020-10-13 |
Abbott Laboratories |
métodos para auxiliar no diagnóstico e avaliar uma lesão cerebral traumática em um indivíduo humano usando uma combinação de gfap e uch-l1
|
JP7344801B2
(ja)
|
2017-12-09 |
2023-09-14 |
アボット・ラボラトリーズ |
グリア原線維性酸性タンパク質(gfap)及び/又はユビキチンカルボキシ末端ヒドロラーゼl1(uch-l1)を使用する、整形外科損傷を負っており、軽度外傷性脳損傷(tbi)などの頭部への損傷を負ったか又は負った可能性がある対象についての診断及び査定の一助となるための方法
|
MX2020006155A
(es)
|
2017-12-12 |
2020-08-13 |
Macrogenics Inc |
Moleculas de union a cd-16 biespecificas y su uso en el tratamiento de enfermedades.
|
CN109954136B
(zh)
*
|
2017-12-14 |
2023-05-02 |
深圳市中科艾深医药有限公司 |
人sDR5-Fc重组融合蛋白作为脑卒中治疗药物的应用
|
US11802154B2
(en)
|
2017-12-20 |
2023-10-31 |
Alexion Pharmaceuticals, Inc. |
Humanized anti-CD200 antibodies and uses thereof
|
JP7369127B2
(ja)
|
2017-12-28 |
2023-10-25 |
ナンジン レジェンド バイオテック カンパニー,リミテッド |
Tigitに対する単一ドメイン抗体及びその変異体
|
JP7437303B2
(ja)
|
2017-12-29 |
2024-02-22 |
アボット・ラボラトリーズ |
外傷性脳損傷を診断及び査定するための、新規のバイオマーカー及び方法
|
WO2019140116A2
(en)
|
2018-01-10 |
2019-07-18 |
Rubius Therapeutics, Inc. |
Amplifiable rnas for therapeutic cell systems
|
KR20200120641A
(ko)
|
2018-01-15 |
2020-10-21 |
난징 레전드 바이오테크 씨오., 엘티디. |
Pd-1에 대한 단일-도메인 항체 및 이의 변이체
|
BR112020016169A2
(pt)
|
2018-02-08 |
2020-12-15 |
Genentech, Inc. |
Moléculas de ligação ao antígeno biespecíficas, ácido nucleico isolado, vetor, célula hospedeira, métodos para produzir a molécula de ligação, conjunto de ácidos nucleicos isolados, conjunto de vetores, conjunto de células hospedeiras, imunoconjugado, composição, uso da molécula de ligação, métodos para tratar ou retardar a progressão de um câncer, métodos para aperfeiçoar a função imune e kit
|
US20210139582A1
(en)
*
|
2018-02-13 |
2021-05-13 |
The Brigham And Women's Hospital, Inc. |
Therapeutic fcrn-based bispecific monoclonal antibodies
|
KR20230020023A
(ko)
|
2018-03-14 |
2023-02-09 |
서피스 온콜로지, 인크. |
Cd39에 결합하는 항체 및 이의 용도
|
CA3093740A1
(en)
|
2018-03-22 |
2019-09-26 |
Surface Oncology, Inc. |
Anti-il-27 antibodies and uses thereof
|
US11780926B2
(en)
|
2018-03-22 |
2023-10-10 |
Universität Stuttgart |
Multivalent binding molecules
|
GB201804701D0
(en)
|
2018-03-23 |
2018-05-09 |
Gammadelta Therapeutics Ltd |
Lymphocytes expressing heterologous targeting constructs
|
WO2019210153A1
(en)
|
2018-04-27 |
2019-10-31 |
Novartis Ag |
Car t cell therapies with enhanced efficacy
|
EP3788369A1
(en)
|
2018-05-01 |
2021-03-10 |
Novartis Ag |
Biomarkers for evaluating car-t cells to predict clinical outcome
|
CN108404132A
(zh)
*
|
2018-05-11 |
2018-08-17 |
厦门大学 |
Ifna4与ifna10基因在克罗恩病中的应用
|
WO2019227003A1
(en)
|
2018-05-25 |
2019-11-28 |
Novartis Ag |
Combination therapy with chimeric antigen receptor (car) therapies
|
CN108508216B
(zh)
*
|
2018-06-06 |
2020-08-07 |
暨南大学 |
抗人bFGF纳米抗体检测bFGF的方法及试剂盒
|
EP3802825A1
(en)
|
2018-06-08 |
2021-04-14 |
Intellia Therapeutics, Inc. |
Compositions and methods for immunooncology
|
BR112020025048A2
(pt)
|
2018-06-13 |
2021-04-06 |
Novartis Ag |
Receptores de antígeno quimérico de bcma e usos dos mesmos
|
US20230041197A1
(en)
|
2018-06-20 |
2023-02-09 |
Progenity, Inc. |
Treatment of a disease of the gastrointestinal tract with an immunomodulator
|
US20230009902A1
(en)
|
2018-06-20 |
2023-01-12 |
Progenity, Inc. |
Treatment of a disease or condition in a tissue orginating from the endoderm
|
JP7397445B2
(ja)
|
2018-06-26 |
2023-12-13 |
協和キリン株式会社 |
Cell Adhesion Molecule3に結合する抗体
|
CN112424357A
(zh)
|
2018-06-26 |
2021-02-26 |
协和麒麟株式会社 |
与硫酸软骨素蛋白聚糖5结合的抗体
|
AR116109A1
(es)
|
2018-07-10 |
2021-03-31 |
Novartis Ag |
Derivados de 3-(5-amino-1-oxoisoindolin-2-il)piperidina-2,6-diona y usos de los mismos
|
WO2020033926A2
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
US20210388089A1
(en)
|
2018-08-09 |
2021-12-16 |
Compass Therapeutics Llc |
Antigen binding agents that bind cd277 and uses thereof
|
WO2020033925A2
(en)
|
2018-08-09 |
2020-02-13 |
Compass Therapeutics Llc |
Antibodies that bind cd277 and uses thereof
|
SG11202101173TA
(en)
|
2018-08-13 |
2021-03-30 |
Inhibrx Inc |
Ox40-binding polypeptides and uses thereof
|
AU2019326740A1
(en)
|
2018-08-21 |
2021-03-18 |
Citryll B.V. |
Antibodies binding to citrullinated histone 2A and/or 4
|
US20210253666A1
(en)
|
2018-08-30 |
2021-08-19 |
TCR2 Therapeutics Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
BR112021003305A2
(pt)
|
2018-08-31 |
2021-05-25 |
Novartis Ag |
métodos para produzir células que expressam receptor de antígeno quimérico
|
EP3844265A2
(en)
|
2018-08-31 |
2021-07-07 |
Novartis AG |
Methods of making chimeric antigen receptor-expressing cells
|
AU2019331024A1
(en)
|
2018-08-31 |
2021-03-18 |
Regeneron Pharmaceuticals, Inc. |
Dosing strategy that mitigates cytokine release syndrome for CD3/C20 bispecific antibodies
|
US20220098613A1
(en)
|
2018-09-12 |
2022-03-31 |
Fred Hutchinson Cancer Research Center |
Reducing cd33 expression to selectively protect therapeutic cells
|
JP7425049B2
(ja)
|
2018-09-25 |
2024-01-30 |
ハープーン セラピューティクス,インク. |
Dll3結合タンパク質および使用方法
|
US20220047633A1
(en)
|
2018-09-28 |
2022-02-17 |
Novartis Ag |
Cd22 chimeric antigen receptor (car) therapies
|
US20210347851A1
(en)
|
2018-09-28 |
2021-11-11 |
Novartis Ag |
Cd19 chimeric antigen receptor (car) and cd22 car combination therapies
|
US20220144941A1
(en)
|
2018-10-16 |
2022-05-12 |
UCB Biopharma SRL |
Method for the treatment of myasthenia gravis
|
MX2021005594A
(es)
|
2018-11-13 |
2021-10-22 |
Compass Therapeutics Llc |
Constructos multiespecificos de union contra moleculas de puntos de control y usos de los mismos.
|
WO2020118011A1
(en)
|
2018-12-06 |
2020-06-11 |
Alexion Pharmaceuticals, Inc. |
Anti-alk2 antibodies and uses thereof
|
WO2020128972A1
(en)
|
2018-12-20 |
2020-06-25 |
Novartis Ag |
Dosing regimen and pharmaceutical combination comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
SG11202106393SA
(en)
|
2018-12-24 |
2021-07-29 |
Sanofi Sa |
Pseudofab-based multispecific binding proteins
|
KR20210131312A
(ko)
|
2019-01-16 |
2021-11-02 |
콤파스 테라퓨틱스 엘엘씨 |
인간 cd137에 결합하는 항체의 제제 및 이의 용도
|
GB201900732D0
(en)
|
2019-01-18 |
2019-03-06 |
Ucb Biopharma Sprl |
Antibodies
|
KR20210120048A
(ko)
|
2019-01-28 |
2021-10-06 |
사노피 |
다발성 골수종의 치료 방법
|
US20220144807A1
(en)
|
2019-02-15 |
2022-05-12 |
Novartis Ag |
3-(1-oxo-5-(piperidin-4-yl)isoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
CN113329792A
(zh)
|
2019-02-15 |
2021-08-31 |
诺华股份有限公司 |
取代的3-(1-氧代异吲哚啉-2-基)哌啶-2,6-二酮衍生物及其用途
|
EP3927371A1
(en)
|
2019-02-22 |
2021-12-29 |
Novartis AG |
Combination therapies of egfrviii chimeric antigen receptors and pd-1 inhibitors
|
AU2020229806A1
(en)
|
2019-02-25 |
2021-07-29 |
Novartis Ag |
Mesoporous silica particles compositions for viral delivery
|
WO2020180695A1
(en)
|
2019-03-01 |
2020-09-10 |
Abbott Laboratories |
Methods for predicting major adverse cardiovascular events in subjects with coronary artery disease
|
KR102588292B1
(ko)
|
2019-03-15 |
2023-10-11 |
카티전 테라퓨틱스, 인코포레이티드 |
항-bcma 키메라 항원 수용체
|
GB201903767D0
(en)
|
2019-03-19 |
2019-05-01 |
Quadrucept Bio Ltd |
Multimers, tetramers & octamers
|
CN109811064B
(zh)
*
|
2019-04-02 |
2023-12-05 |
华南农业大学 |
一种与鸡j亚群禽白血病抗性相关的分子标记及其应用
|
US20220168389A1
(en)
|
2019-04-12 |
2022-06-02 |
Novartis Ag |
Methods of making chimeric antigen receptor-expressing cells
|
EP3959320A1
(en)
|
2019-04-24 |
2022-03-02 |
Novartis AG |
Compositions and methods for selective protein degradation
|
CN110075322B
(zh)
*
|
2019-05-20 |
2021-07-06 |
复旦大学附属妇产科医院 |
一种靶向GnRH受体的近红外荧光成像探针及其制备方法与应用
|
JP2022539248A
(ja)
|
2019-07-02 |
2022-09-07 |
フレッド ハッチンソン キャンサー リサーチ センター |
組換えad35ベクター及び関連遺伝子治療改善
|
CN110478474B
(zh)
*
|
2019-08-21 |
2020-06-02 |
启辰生生物科技(珠海)有限公司 |
免疫调节剂、疫苗、细胞及应用
|
WO2021035170A1
(en)
|
2019-08-21 |
2021-02-25 |
Precision Biosciences, Inc. |
Compositions and methods for tcr reprogramming using fusion proteins
|
TW202124444A
(zh)
|
2019-09-16 |
2021-07-01 |
美商表面腫瘤學公司 |
抗cd39抗體組合物及方法
|
CN110627905B
(zh)
*
|
2019-09-18 |
2021-04-27 |
中国医学科学院肿瘤医院 |
靶向vegf与egfr的双功能融合蛋白及其应用
|
TW202128752A
(zh)
|
2019-09-25 |
2021-08-01 |
美商表面腫瘤學公司 |
抗il﹘27抗體及其用途
|
CN110988354A
(zh)
*
|
2019-11-15 |
2020-04-10 |
同济大学 |
一种分泌蛋白Caspase1在早期心梗诊断试剂中的应用
|
AR120566A1
(es)
|
2019-11-26 |
2022-02-23 |
Novartis Ag |
Receptores de antígeno quiméricos y sus usos
|
GB201917480D0
(en)
|
2019-11-29 |
2020-01-15 |
Univ Oxford Innovation Ltd |
Antibodies
|
US20230056470A1
(en)
|
2019-12-20 |
2023-02-23 |
Novartis Ag |
Uses of anti-tgf-beta antibodies and checkpoint inhibitors for the treatment of proliferative diseases
|
AU2021205877A1
(en)
|
2020-01-06 |
2022-06-09 |
Vaccinex, Inc. |
Anti-CCR8 antibodies and uses thereof
|
US20230111593A1
(en)
|
2020-02-14 |
2023-04-13 |
Novartis Ag |
Method of predicting response to chimeric antigen receptor therapy
|
JP2023527609A
(ja)
|
2020-02-21 |
2023-06-30 |
ハープーン セラピューティクス,インク. |
Flt3結合タンパク質および使用方法
|
BR112022017148A2
(pt)
|
2020-02-27 |
2022-11-08 |
Novartis Ag |
Métodos para produzir células que expressam receptor de antígeno quimérico
|
JP2023515211A
(ja)
|
2020-02-27 |
2023-04-12 |
ノバルティス アーゲー |
キメラ抗原受容体発現細胞を作製する方法
|
CN111269326A
(zh)
|
2020-02-28 |
2020-06-12 |
南京北恒生物科技有限公司 |
新型嵌合抗原受体及其用途
|
JP2023517889A
(ja)
|
2020-03-10 |
2023-04-27 |
マサチューセッツ インスティテュート オブ テクノロジー |
NPM1c陽性がんの免疫療法のための組成物および方法
|
WO2021190980A1
(en)
|
2020-03-22 |
2021-09-30 |
Quadrucept Bio Limited |
Multimers for viral strain evolution
|
RU2763178C2
(ru)
*
|
2020-03-23 |
2021-12-28 |
Акционерное Общество "Р-Фарм" |
Антитела для лабораторной диагностики концентрации интерлейкина-11
|
CA3175523A1
(en)
|
2020-04-13 |
2021-10-21 |
Antti Virtanen |
Methods, complexes and kits for detecting or determining an amount of a .beta.-coronavirus antibody in a sample
|
WO2021231655A1
(en)
|
2020-05-12 |
2021-11-18 |
Lyell Immunopharma, Inc. |
Chimeric antigen receptor spacers
|
CN111849910B
(zh)
|
2020-05-27 |
2021-06-15 |
南京北恒生物科技有限公司 |
工程化免疫细胞及其用途
|
AU2021286676A1
(en)
|
2020-06-11 |
2022-09-08 |
Bioheng Therapeutics Limited |
Engineered immune cell expressing NK inhibitory molecule and use thereof
|
CN116096862A
(zh)
|
2020-06-11 |
2023-05-09 |
诺华股份有限公司 |
Zbtb32抑制剂及其用途
|
IL298402A
(en)
|
2020-06-19 |
2023-01-01 |
Hoffmann La Roche |
Antibodies that bind to CD3 and CD19
|
WO2021260528A1
(en)
|
2020-06-23 |
2021-12-30 |
Novartis Ag |
Dosing regimen comprising 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives
|
WO2022010798A1
(en)
|
2020-07-06 |
2022-01-13 |
Kiromic BioPharma, Inc. |
Mesothelin isoform binding molecules and chimeric pd1 receptor molecules, cells containing the same and uses thereof
|
JP2023527530A
(ja)
|
2020-07-15 |
2023-06-29 |
南京北恒生物科技有限公司 |
同種異系移植のための操作された免疫細胞
|
AU2021308712A1
(en)
|
2020-07-16 |
2023-02-02 |
Novartis Ag |
Anti-betacellulin antibodies, fragments thereof, and multi-specific binding molecules
|
CN114057890A
(zh)
|
2020-07-31 |
2022-02-18 |
南京北恒生物科技有限公司 |
新型共刺激结构域及其用途
|
GB202011993D0
(en)
|
2020-07-31 |
2020-09-16 |
Adc Therapeutics Sa |
ANTI-IL 13Ra2 antibodies
|
EP4188549A1
(en)
|
2020-08-03 |
2023-06-07 |
Novartis AG |
Heteroaryl substituted 3-(1-oxoisoindolin-2-yl)piperidine-2,6-dione derivatives and uses thereof
|
WO2022031804A1
(en)
|
2020-08-04 |
2022-02-10 |
Abbott Laboratories |
Improved methods and kits for detecting sars-cov-2 protein in a sample
|
GB202012326D0
(en)
|
2020-08-07 |
2020-09-23 |
Citryll B V |
Diagnostic
|
CN112063588A
(zh)
|
2020-08-13 |
2020-12-11 |
南京北恒生物科技有限公司 |
工程化免疫细胞及其用途
|
MX2023002107A
(es)
|
2020-08-21 |
2023-03-15 |
Novartis Ag |
Composiciones y metodos para la generacion in vivo de celulas que expresan car.
|
CN114163532A
(zh)
|
2020-09-10 |
2022-03-11 |
南京北恒生物科技有限公司 |
包含新型共刺激结构域的嵌合抗原受体及其用途
|
CA3191403A1
(en)
|
2020-10-13 |
2022-04-21 |
Edward Hsia |
Bispecific molecules and methods of treatment using the same
|
WO2022089767A1
(en)
|
2020-11-02 |
2022-05-05 |
UCB Biopharma SRL |
Use of anti-trem1 neutralizing antibodies for the treatment of motor neuron neurodegenerative disorders
|
CN114525259A
(zh)
|
2020-11-03 |
2022-05-24 |
南京北恒生物科技有限公司 |
靶向cd7的嵌合抗原受体及其用途
|
CN112300282A
(zh)
|
2020-11-03 |
2021-02-02 |
南京北恒生物科技有限公司 |
靶向cd7的人源化抗体及其用途
|
IL302700A
(en)
|
2020-11-13 |
2023-07-01 |
Novartis Ag |
Combined treatments with cells expressing chimeric antigens (vehicle)
|
WO2022108627A1
(en)
|
2020-11-18 |
2022-05-27 |
Kiromic Biopharma, Inc.Kiromic Biopharma, Inc. |
Gamma-delta t cell manufacturing processes and chimeric pd1 receptor molecules
|
CN114524876A
(zh)
|
2020-11-23 |
2022-05-24 |
南京北恒生物科技有限公司 |
靶向nkg2a的抗体及其用途
|
US20220170948A1
(en)
|
2020-12-01 |
2022-06-02 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a human subject having received a head computerized tomography scan that is negative for a tbi
|
WO2023102384A1
(en)
|
2021-11-30 |
2023-06-08 |
Abbott Laboratories |
Use of one or more biomarkers to determine traumatic brain injury (tbi) in a subject having received a head computerized tomography scan that is negative for a tbi
|
CN112748247A
(zh)
*
|
2020-12-23 |
2021-05-04 |
复旦大学附属华山医院 |
抗体结合剂在制备白癜风病期辅助检测产品中的应用及白癜风病期鉴定用的检测试剂盒
|
WO2022147147A1
(en)
|
2020-12-30 |
2022-07-07 |
Abbott Laboratories |
Methods for determining sars-cov-2 antigen and anti-sars-cov-2 antibody in a sample
|
EP4257610A1
(en)
|
2021-01-12 |
2023-10-11 |
Bioheng Therapeutics Limited |
Ror1-targeting antibody and use thereof
|
JP2024505600A
(ja)
|
2021-02-03 |
2024-02-06 |
モーツァルト セラピューティクス, インコーポレイテッド |
結合剤およびそれを使用する方法
|
JP2024505955A
(ja)
|
2021-02-03 |
2024-02-08 |
バイオヘン セラピューティクス リミテッド |
新型キメラ抗原受容体及びその使用
|
CN112957472B
(zh)
*
|
2021-02-05 |
2021-11-16 |
无锡市第五人民医院 |
靶向ccl19/ccr7的乙型肝炎免疫治疗剂及其用途
|
JP2024510898A
(ja)
|
2021-02-25 |
2024-03-12 |
ライエル・イミュノファーマ・インコーポレイテッド |
Ror1を標的とするキメラ抗原受容体
|
CN112961250B
(zh)
*
|
2021-03-01 |
2023-06-06 |
长春金赛药业有限责任公司 |
抗体融合蛋白及其应用
|
WO2022184659A1
(en)
|
2021-03-01 |
2022-09-09 |
Quadrucept Bio Limited |
Antibody domains & multimers
|
TW202304979A
(zh)
|
2021-04-07 |
2023-02-01 |
瑞士商諾華公司 |
抗TGFβ抗體及其他治療劑用於治療增殖性疾病之用途
|
CN117279664A
(zh)
|
2021-04-10 |
2023-12-22 |
普方生物制药美国公司 |
Folr1结合剂、其偶联物及其使用方法
|
EP4326768A1
(en)
|
2021-04-23 |
2024-02-28 |
Profoundbio Us Co. |
Anti-cd70 antibodies, conjugates thereof and methods of using the same
|
WO2022229853A1
(en)
|
2021-04-27 |
2022-11-03 |
Novartis Ag |
Viral vector production system
|
EP4085973A1
(en)
|
2021-05-04 |
2022-11-09 |
Citryll B.V. |
Inhibition of eosinophil extracellular traps
|
IL308223A
(en)
|
2021-05-04 |
2024-01-01 |
Citryll B V |
Prevention of eosinophilic traps
|
CA3215856A1
(en)
|
2021-05-07 |
2022-11-10 |
Alison O'neill |
Anti-il-27 antibodies and uses thereof
|
EP4341699A1
(en)
|
2021-05-18 |
2024-03-27 |
Abbott Laboratories |
Methods of evaluating brain injury in a pediatric subject
|
EP4356129A1
(en)
|
2021-06-14 |
2024-04-24 |
Abbott Laboratories |
Methods of diagnosing or aiding in diagnosis of brain injury caused by acoustic energy, electromagnetic energy, an over pressurization wave, and/or blast wind
|
WO2023274342A1
(zh)
*
|
2021-06-30 |
2023-01-05 |
江苏恒瑞医药股份有限公司 |
特异性结合baff和il-12/23的抗原结合分子及用途
|
TW202320857A
(zh)
|
2021-07-06 |
2023-06-01 |
美商普方生物製藥美國公司 |
連接子、藥物連接子及其結合物及其使用方法
|
TW202323521A
(zh)
|
2021-08-20 |
2023-06-16 |
瑞士商諾華公司 |
製備表現嵌合抗原受體的細胞之方法
|
WO2023034777A1
(en)
|
2021-08-31 |
2023-03-09 |
Abbott Laboratories |
Methods and systems of diagnosing brain injury
|
CA3232176A1
(en)
|
2021-09-30 |
2023-04-06 |
Beth MCQUISTON |
Methods and systems of diagnosing brain injury
|
CN113884685B
(zh)
*
|
2021-10-18 |
2023-03-14 |
中国农业大学 |
牛结核病血清学诊断标志物及其临床应用
|
WO2023076876A1
(en)
|
2021-10-26 |
2023-05-04 |
Mozart Therapeutics, Inc. |
Modulation of immune responses to viral vectors
|
WO2023114978A1
(en)
|
2021-12-17 |
2023-06-22 |
Abbott Laboratories |
Systems and methods for determining uch-l1, gfap, and other biomarkers in blood samples
|
US20230213536A1
(en)
|
2021-12-28 |
2023-07-06 |
Abbott Laboratories |
Use of biomarkers to determine sub-acute traumatic brain injury (tbi) in a subject having received a head computerized tomography (ct) scan that is negative for a tbi or no head ct scan
|
WO2023150652A1
(en)
|
2022-02-04 |
2023-08-10 |
Abbott Laboratories |
Lateral flow methods, assays, and devices for detecting the presence or measuring the amount of ubiquitin carboxy-terminal hydrolase l1 and/or glial fibrillary acidic protein in a sample
|
WO2023209568A1
(en)
|
2022-04-26 |
2023-11-02 |
Novartis Ag |
Multispecific antibodies targeting il-13 and il-18
|
WO2023214325A1
(en)
|
2022-05-05 |
2023-11-09 |
Novartis Ag |
Pyrazolopyrimidine derivatives and uses thereof as tet2 inhibitors
|
CN117285647A
(zh)
*
|
2022-06-17 |
2023-12-26 |
南京北恒生物科技有限公司 |
靶向ccr8的嵌合抗原受体及其用途
|
WO2024006876A1
(en)
|
2022-06-29 |
2024-01-04 |
Abbott Laboratories |
Magnetic point-of-care systems and assays for determining gfap in biological samples
|
WO2024030956A2
(en)
|
2022-08-03 |
2024-02-08 |
Mozart Therapeutics, Inc. |
Cd39-specific binding agents and methods of using the same
|
WO2024059708A1
(en)
|
2022-09-15 |
2024-03-21 |
Abbott Laboratories |
Biomarkers and methods for differentiating between mild and supermild traumatic brain injury
|
WO2024056809A1
(en)
|
2022-09-15 |
2024-03-21 |
Novartis Ag |
Treatment of autoimmune disorders using chimeric antigen receptor therapy
|
WO2024061158A1
(en)
*
|
2022-09-20 |
2024-03-28 |
Everest Medicines (China) Co., Ltd. |
Slit2 related compositions and methods
|
WO2024089639A1
(en)
|
2022-10-26 |
2024-05-02 |
Novartis Ag |
Lentiviral formulations
|
GB202216503D0
(en)
|
2022-11-05 |
2022-12-21 |
Quadrucept Bio Ltd |
Non-human vertebrates & cells
|
CN116286669B
(zh)
*
|
2023-03-23 |
2023-09-22 |
江南大学 |
一株分泌托拉塞米单克隆抗体的杂交瘤细胞株及其应用
|